




Recombinant CRISPR Cas9 GMP-Grade

Catalog #GMP-CAS-EE110

FDA DRUG MASTER FILES (DMF) #036578




KACTUS has successfully designed a highly-active CRISPR Cas9 protein. Using our protein engineering platform, our Cas9 has undergone codon optimization, nuclear localization signal (NLS) design, and optimization of *E. coli* expression and purification.



In vitro Cleavage

Cas9 cleaves substrate DNA standard via *in vitro* cleavage experiment. Results show the cleavage activity of KACTUS Cas9 is equivalent to that of leading suppliers.

High Editing Efficacy in Multiple Cell Types



Ex vivo Gene Knockout

Gene knockout efficiency analyzed in nucleofected 293T, Jurkat, and T cells using TIDE analysis. Results show greater than 85% editing efficacy across all three cell types, comparable to a leading supplier.

www.stratech.co.uk

+44 (0) 1638 782600

orders@stratech.co.uk

@stratech_uk

@stratechscientifictd

@stratech-scientific-ltd